The investigation by Levi & Korsinsky into Harmony Biosciences for potential securities fraud is significant, as it follows a report by Scorpion Capital that raised concerns about the company's drug, Wakix. This could lead to legal challenges and regulatory scrutiny, likely impacting investor confidence and causing short-term stock price volatility.